Newsletter of 25 Mar, 2004
EFB Section of Medicines Development, Board established
Dear Member of EFB Section of Medicines Development
Firstly thank you for joining the Section. We are now more than 160 members within only a couple of months!
I would like to update you on the ongoing activities.
The initiative has gained a lot of interest and is seen by the European Commission as a potential European Technology Platform which will be a new instrument in FP7. Further the initiative is seen an example of coordination between the EU Framework Programme and EUREKA
We have just had the first meeting in the section where those who had expressed interest in joining the Board of the section including representatives from the European Commission and EUREKA.
The Board consists of the following members:
Jørgen Dirach, Novo Nordisk (Chairman),
Denmark
Lilia
Alberghina, University of Milano-Bicocca, Italy
Vic
Ilag, Xerion Pharmaceuticals, Germany
Andreani
Odysseos, University
of Cyprus, Cyprus
Ove
Pedersen, Alk-abelló, Denmark
Hans
Günther Schaefer, Boehringer
Ingelheim, Germany
Patrick
Keohane, Astra Zeneca, Sweden/UK
Menno
Van Der Waart, NV
Organon, the Netherlands
Türkan
Eldam, Hacettepe University, Turkey
Stephen
Little, Dxs Ltd., UK
Iman
Barilero, Johnson & Johnson Pharmaceutical Research and Development,
UK
It was agreed to keep seats open on the Board open for a few additional, relevant stakeholders.
The same group will be behind the
application for the EUREKA Definition phase project. The application is
being prepared for submission in April.
A group was formed to evaluate the submitted project proposals and decide
on future calls.
We are now consolidating the Section writing statutes etc. and ensuring
collaboration with organisations pursuing similar goals.
Kind regards, Jorgen Dirach
Dr. Jørgen Dirach, MD, MBA, MFPM
Section Chairman
Novo Nordisk A/S, Corporate Research Affairs
Novo Allé
DK-2880 Bagsværd
Tel: +45 4442 3355 direct, Fax: +45 4442 1286